About Nucleix
Nucleix is a company based in Rehovot (Israel) founded in 2008. Nucleix has raised $85.5 million across 9 funding rounds from investors including BlackRock, Orbimed and RA Capital. Nucleix offers products and services including Bladder EpiCheck and Lung EpiCheck. Nucleix operates in a competitive market with competitors including Guardant Health, GRAIL, Delfi Diagnostics, BillionToOne and Thrive Earlier Detection, among others.
- Headquarter Rehovot, Israel
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$85.5 M (USD)
in 9 rounds
-
Latest Funding Round
$22 M (USD), Series C
Dec 30, 2021
-
Investors
BlackRock
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nucleix
Nucleix offers a comprehensive portfolio of products and services, including Bladder EpiCheck and Lung EpiCheck.
Non-invasive test for monitoring bladder cancer recurrence.
Blood test for early detection of lung cancer in high-risk individuals.
People of Nucleix
Unlock access to complete
Unlock access to complete
Funding Insights of Nucleix
Nucleix has successfully raised a total of $85.5M across 9 strategic funding rounds. The most recent funding activity was a Series C round of $22 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Nucleix
Nucleix has secured backing from 11 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include BlackRock, Orbimed and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
LYFE Capital is recognized as a premier healthcare investment platform.
|
Locked | Locked | Locked |
Investor details for Nucleix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nucleix
Investment portfolio details for Nucleix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Nucleix
Detailed financials for Nucleix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nucleix Comparisons
Peer comparison for Nucleix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nucleix
Nucleix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Delfi Diagnostics, BillionToOne and Thrive Earlier Detection, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Provider of DNA sequencing for cancer detection
|
|
| Locked | Locked | Locked |
Provider of cell-free cancer liquid biopsy test
|
|
| Locked | Locked | Locked |
Blood-based liquid biopsy tests for multiple cancer detection are provided.
|
Detailed competitors of Nucleix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nucleix
Complete news archive for Nucleix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nucleix
Nucleix was founded in 2008 and raised its 1st funding round 6 years after it was founded.
Nucleix is headquartered in Rehovot, Israel. It is registered at Rehovot, Central District, Israel.
Nucleix is a funded company, having raised a total of $85.5M across 9 funding rounds to date.
Nucleix was founded in 2008 in Rehovot, Israel, within the biotechnology sector focused on oncology diagnostics. Non-invasive tests for cancer detection are created by leveraging DNA methylation patterns through proprietary biomarker assays. The initial product, Bladder EpiCheck, is applied for bladder cancer diagnosis. Tests for colorectal and lung cancer have also been developed to support early detection in clinical settings.
Nucleix's top competitors include Guardant Health, GRAIL and BillionToOne.
Nucleix offers Bladder EpiCheck and Lung EpiCheck.
Nucleix has 11 investors. Key investors include BlackRock, Orbimed, RA Capital, European Union, and DSC Investment.